Alkermes Plc (ALKS) Receives $51.44 Average PT from Brokerages
Alkermes Plc (NASDAQ:ALKS) has been given a consensus rating of “Buy” by the fifteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $50.89.
A number of research firms have weighed in on ALKS. Piper Jaffray Companies began coverage on shares of Alkermes in a research note on Monday, November 5th. They issued a “neutral” rating and a $40.00 price objective on the stock. BidaskClub lowered shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. ValuEngine raised shares of Alkermes from a “sell” rating to a “hold” rating in a research note on Friday, October 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $41.00 price objective (down from $46.00) on shares of Alkermes in a research note on Monday, November 5th. Finally, Credit Suisse Group dropped their price objective on shares of Alkermes from $57.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, July 27th.
In other news, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $44.58, for a total value of $44,580.00. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at $356,640. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 3,000 shares of company stock valued at $124,510. 5.34% of the stock is currently owned by corporate insiders.
Shares of Alkermes stock traded down $1.33 during trading hours on Monday, reaching $37.67. The company’s stock had a trading volume of 820,584 shares, compared to its average volume of 1,090,281. Alkermes has a one year low of $36.67 and a one year high of $71.22. The firm has a market capitalization of $6.07 billion, a price-to-earnings ratio of -101.81 and a beta of 1.61. The company has a current ratio of 2.85, a quick ratio of 2.56 and a debt-to-equity ratio of 0.24.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Tuesday, October 23rd. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.15. Alkermes had a negative net margin of 13.23% and a negative return on equity of 0.12%. The firm had revenue of $248.72 million for the quarter, compared to analyst estimates of $236.70 million. During the same period last year, the firm earned $0.03 earnings per share. The business’s quarterly revenue was up 14.4% compared to the same quarter last year. On average, research analysts forecast that Alkermes will post -0.5 EPS for the current year.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Read More: Balance Sheet
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.